Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿ø¹ßº´¼Ò ºÒ¸íÀÇ °æºÎ¸²ÇÁÀý ÀüÀÌÀÇ Ä¡·á°á°ú Treatment Outcome of Metastatic Carcinoma of Cervical Lymph Node from an Unknown Primary

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2005³â 23±Ç 3È£ p.137 ~ 142
¼Ò¼Ó »ó¼¼Á¤º¸
±è±Ôº¸/Kim KB ÁöÀDZÔ/¿ìÈ«±Õ/±è±¤Çö/¼º¸íÈÆ/Çã´ë¼®/¹ÚÂùÀÏ/Chie EK/Wu HG/Kim KH/Sung MW/Heo DS/Park CI

Abstract

¸ñ Àû: ¿ø¹ßº´¼Ò ºÒ¸íÀÇ °æºÎ¸²ÇÁÀý ÀüÀÌÀÇ Ä¡·á´Â °¢ ±â°üµéÀÇ Ä¡·á¿øÄ¢¿¡ µû¶ó °æºÎ¸²ÇÁÀýû¼Ò¼ú, ¸²ÇÁÀýÀýÁ¦¼ú, ¹æ»ç¼±Ä¡·á ¹× Ç×¾ÏÈ­ÇÐÄ¡·á µî ´Ù¾çÇÑ Á¶ÇÕÀÇ Ä¡·á°¡ Àû¿ëµÇ°í ÀÖ´Ù. ÀúÀÚµéÀº ¼­¿ï´ëÇб³º´¿ø¿¡¼­ ¿ø¹ßº´¼Ò ºÒ¸íÀÇ °æºÎ¸²ÇÁÀý ÀüÀÌÀÇ Ä¡·á¼ºÀûÀ» ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1981³â 7¿ùºÎÅÍ 1999³â 6¿ù±îÁö ¼­¿ï´ëÇб³º´¿ø ¹æ»ç¼±Á¾¾çÇаú¿¡¼­ ±ÙÄ¡Àû ¶Ç´Â ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 39¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. ¹æ»ç¼±Ä¡·á°¡ 12¸í¿¡¼­, ¼±ÇàÇ×¾ÏÈ­Çпä¹ý ¹× ¹æ»ç¼±Ä¡·á°¡ 8¸í¿¡¼­, ¼ö¼ú ¹× ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á°¡ 18¸í¿¡¼­ ½ÃÇàµÇ¾ú°í, 1¸íÀº ¼±ÇàÇ×¾ÏÈ­Çпä¹ý, °æºÎ¸²ÇÁÀýû¼Òû¼ú ¹× ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ ¹Þ¾Ò´Ù. ¼ºº°Àº ³²ÀÚ°¡ 31¸í, ¿©ÀÚ°¡ 8¸íÀ̾ú°í, ¿¬·ÉÀÇ Áß¾Ó°ªÀº 55¼¼¿´´Ù.

°á °ú: Àüü ȯÀÚÀÇ 5³â »ýÁ¸À²Àº 55%¿´´Ù. Ä¡·á¹æ¹ý¿¡ µû¶ó ºÐ¼®Çغ¸¾ÒÀ» ¶§, ¼ö¼ú+¹æ»ç¼±Ä¡·á°¡ ¹æ»ç¼±Ä¡·á ´Üµ¶ ȤÀº Ç×¾ÏÈ­Çпä¹ý+¹æ»ç¼±Ä¡·á¿¡ ºñÇØ ¿ì¿ùÇÑ 5³â ¹«º´»ýÁ¸À²À» º¸°íÇÏ¿´´Ù (75% vs. 48% vs. 19%). ±× ¿Ü¿¡ ¿ø¹ßº´¼Ò ¹ßÇö¿©ºÎ°¡ ¹«º´»ýÁ¸À²¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ÁÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

°á ·Ð: ¿ø¹ßº´¼Ò ºÒ¸íÀÇ °æºÎ¸²ÇÁÀý ÀüÀÌÀÇ Ä¡·á¿¡ À־ ¼ö¼úÀû ÀýÁ¦¼ú ¹× ¹æ»ç¼±Ä¡·áÀÇ º´¿ë¿ä¹ýÀÌ ¹æ»ç¼±Ä¡·á¡¾Ç×¾ÏÈ­Çпä¹ý¿¡ ºñÇØ ¿ì¿ùÇÑ ¹«º´»ýÁ¸À²À» º¸¿©ÁÖ¾ú´Ù. Ç×¾ÏÈ­Çпä¹ýÀÇ È¿°ú¿¡ ´ëÇؼ­´Â Ãß°¡ ¿¬±¸°¡ ¿ä¸ÁµÈ´Ù.

Purpose: To analyze the outcome of radiation therapy for patients with a metastatic carcinoma of cervical lymph nodes from an unknown primary (MUO), and identify the prognostic factors for these patients.

Materials and Methods: Between July 1981 and June 1999, 39 patients with MUO underwent radiation therapy with curative intent. Twelve patients were treated with radiation therapy alone (Group 1), 8 with neoadjuvant chemotherapy followed by radiation therapy (Group 2), and 19 with either an excision or neck dissection and postoperative radiation therapy (Group 3). There were 31 males and 8 females, with a median age of 55 years, ranging from 25 to 77 ears. The median duration of follow-up was 38 months, ranging from 3 to 249 months.

Results: The 5-year overall survival rate was 55%. According to the treatment modality, the 5-year disease-free survival rates of Groups 1, 2 and 3 were 48, 19 and 75%, respectively (p=0.0324). In addition to the treatment modality, the appearance of the primary site was a significant prognostic factor for disease-free survival (p=0.0085).

Conclusion: Surgical resection and radiation therapy achieves a superior disease-free survival compared to radiation therapy alone, either with or without chemotherapy. Further investigation is needed to evaluate the role of chemotherapy in the treatment of MUO.

Å°¿öµå

°æºÎ¸²ÇÁÀý ÀüÀÌ; ¿ø¹ßº´¼Ò ºÒ¸í; ¹æ»ç¼±Ä¡·á ;Metastatic carcinoma of cervical lymph node; Unknown primary; Radiation therapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS